Tipifarnib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed or Refractory Peripheral T-Cell Lymphoma
Conditions
Relapsed or Refractory Peripheral T-Cell Lymphoma
Trial Timeline
Feb 25, 2016 → Mar 31, 2021
NCT ID
NCT02464228About Tipifarnib
Tipifarnib is a phase 2 stage product being developed by Kura Oncology for Relapsed or Refractory Peripheral T-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02464228. Target conditions include Relapsed or Refractory Peripheral T-Cell Lymphoma.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed or Refractory Peripheral T-Cell Lymphoma were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04809233 | Pre-clinical | Active |
| NCT04865159 | Phase 1 | Terminated |
| NCT03719690 | Phase 2 | Completed |
| NCT02807272 | Phase 2 | Completed |
| NCT02779777 | Phase 2 | Terminated |
| NCT02464228 | Phase 2 | Completed |
| NCT02383927 | Phase 2 | Completed |
Competing Products
20 competing products in Relapsed or Refractory Peripheral T-Cell Lymphoma